Roman Butler Fullerton & Co. increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 72.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,031 shares of the biotechnology company’s stock after acquiring an additional 6,757 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Corcept Therapeutics were worth $491,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its holdings in shares of Corcept Therapeutics by 9.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,900 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 500 shares during the period. Mutual of America Capital Management LLC raised its holdings in Corcept Therapeutics by 33.3% in the fourth quarter. Mutual of America Capital Management LLC now owns 144,972 shares of the biotechnology company’s stock worth $4,709,000 after purchasing an additional 36,255 shares in the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of Corcept Therapeutics during the fourth quarter valued at about $1,468,000. Strs Ohio boosted its holdings in shares of Corcept Therapeutics by 585.0% in the 4th quarter. Strs Ohio now owns 13,700 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 11,700 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Corcept Therapeutics in the 4th quarter worth approximately $625,000. 93.61% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $30.21, for a total value of $66,462.00. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $30.18, for a total transaction of $150,900.00. Following the sale, the insider now owns 7,314 shares of the company’s stock, valued at approximately $220,736.52. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $30.21, for a total transaction of $66,462.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,550 shares of company stock valued at $1,178,759. 20.50% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Corcept Therapeutics
Corcept Therapeutics Stock Performance
NASDAQ CORT traded up $0.03 during mid-day trading on Tuesday, reaching $34.14. 524,386 shares of the stock were exchanged, compared to its average volume of 1,301,647. Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $39.75. The business’s 50 day moving average is $32.65 and its 200-day moving average is $27.42. The company has a market capitalization of $3.55 billion, a P/E ratio of 32.18 and a beta of 0.44.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.09. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The business had revenue of $163.80 million for the quarter, compared to analyst estimates of $155.14 million. During the same period in the prior year, the company posted $0.25 EPS. The company’s revenue for the quarter was up 39.1% on a year-over-year basis. Equities analysts predict that Corcept Therapeutics Incorporated will post 1.03 earnings per share for the current fiscal year.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- 5 discounted opportunities for dividend growth investors
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- ETF Screener: Uses and Step-by-Step Guide
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.